Author: admin

JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SFA Therapeutics, a clinical-stage biotech using a first-in-class immuno-modulation technology platform, announced positive results from their SFA-002 Phase 1b cohort 1 clinical trial. SFA’s oral pill SFA-002 has the potential to be disease-modifying, with durable responses and an excellent safety profile. SFA-002 simultaneously acts on multiple therapeutic pathways, unlike other drugs on the market which target a single...

Abstract Cancer is a multi-step process that can be viewed as a cellular and immunological shift away from homeostasis in response to selected infectious agents, mutations, diet, and environmental carcinogens. Homeostasis, which contributes importantly to the definition of “health,” is maintained, in part by the production of short-chain fatty acids (SCFAs), which are metabolites of specific gut bacteria. Alteration in the composition of gut bacteria, or...

READ MORE...